La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Glenmark Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 5/6
Glenmark Pharmaceuticals ha un patrimonio netto totale di ₹78.5B e un debito totale di ₹12.3B, che porta il suo rapporto debito/patrimonio netto a 15.7%. Le sue attività totali e le sue passività totali sono rispettivamente ₹143.6B e ₹65.1B. L'EBIT di Glenmark Pharmaceuticals è ₹7.9B rendendo il suo rapporto di copertura degli interessi 1.8. Ha liquidità e investimenti a breve termine pari a ₹16.6B.
Informazioni chiave
15.7%
Rapporto debito/patrimonio netto
₹12.31b
Debito
| Indice di copertura degli interessi | 3.7x |
| Contanti | ₹16.59b |
| Patrimonio netto | ₹78.48b |
| Totale passività | ₹65.11b |
| Totale attività | ₹143.59b |
Aggiornamenti recenti sulla salute finanziaria
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20Recent updates
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( ₹74.3B ) di GLENMARK superano le sue passività a breve termine ( ₹58.2B ).
Passività a lungo termine: Le attività a breve termine di GLENMARK ( ₹74.3B ) superano le sue passività a lungo termine ( ₹6.9B ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: GLENMARK ha più liquidità del suo debito totale.
Riduzione del debito: Il rapporto debito/patrimonio netto di GLENMARK si è ridotto da 64.7% a 15.7% negli ultimi 5 anni.
Copertura del debito: Il flusso di cassa operativo di GLENMARK è negativo, pertanto il debito non è ben coperto.
Copertura degli interessi: I pagamenti degli interessi sul debito di GLENMARK sono ben coperti dall'EBIT ( 3.7 x copertura).